@article{Alan H. Shih_Stephen S. Chung_Emily K. Dolezal_Su-Jiang Zhang_Omar I. Abdel-Wahab_Christopher Y. Park_Stephen D. Nimer_Ross L. Levine_Virginia M. Klimek_2013, place={Pavia, Italy}, title={Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia}, volume={98}, url={https://haematologica.org/article/view/6692}, DOI={10.3324/haematol.2012.076729}, abstractNote={Therapy-related myelodysplastic syndromes and acute myelogenous leukemia comprise a poor-risk subset of myelodysplastic syndromes and acute myelogenous leukemia. Large-scale mutation profiling efforts in <em>de novo</em> myelodysplastic syndromes have identified mutations that correlate with clinical features, but such mutations have not been investigated in therapy-related myelodysplastic syndromes and acute myelogenous leukemia. Genomic DNA from 38 patient samples were subjected to high throughput polymerase chain reaction and sequenced for <em>TP53, TET2, DNMT3A, ASXL1, IDH1, IDH2, EZH2, EED, SUZ12, RBBP4, SRSF2, U2AF35</em>, and <em>SF3B1</em>. We identified somatic mutations in 16 of 38 (42%) patients. TP53 mutations were the most common lesion, detected in 8 of 38 (21%) patients, followed by TET2 in 4 of 38 (10.5%). Cases with a <em>TP53</em> mutation or loss of the <em>TP53</em> locus had a worse overall survival compared to those with wild-type TP53 (8.8 <em>vs.</em> 37.4 months; <em>P</em&gt;=0.0035).}, number={6}, journal={Haematologica}, author={Alan H. Shih and Stephen S. Chung and Emily K. Dolezal and Su-Jiang Zhang and Omar I. Abdel-Wahab and Christopher Y. Park and Stephen D. Nimer and Ross L. Levine and Virginia M. Klimek}, year={2013}, month={May}, pages={908-912} }